Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.
Giovanna CarràAntonio CartellàBeatrice MaffeoAlessandro MorottiPublished in: Blood and lymphatic cancer : targets and therapy (2019)
Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.
Keyphrases
- chronic myeloid leukemia
- stem cells
- cell therapy
- end stage renal disease
- ejection fraction
- dendritic cells
- tyrosine kinase
- bone marrow
- newly diagnosed
- acute myeloid leukemia
- chronic kidney disease
- prognostic factors
- papillary thyroid
- peritoneal dialysis
- patient reported outcomes
- immune response
- drug induced
- binding protein
- protein kinase
- single molecule
- small molecule
- squamous cell
- childhood cancer